Development and validation of the Short-Form Survivor Unmet Needs Survey (SF-SUNS)

Campbell, H. Sharon; Hall, Alix; Sanson‐Fisher, Rob; Barker, Daniel; Turner, Donna; Taylor‐Brown, Jill

doi:10.1007/s00520-013-2061-7

Cited by 46 publications

(63 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five needs assessment tools were identified as having been used with cancer survivors in the post‐treatment setting. These included the Survivor Unmet Needs Survey (SUNS) (Campbell et al., ; Hall, D'Este, Tzelepis, Sanson‐Fisher, & Lynagh, ), the Short Form Survivor Unmet Needs Survey (SF‐SUNS) (Campbell et al., ), Cancer Survivors Unmet Needs (CaSUN) (Hodgkinson et al., ), Cancer Needs Questionnaire Young People (CNQ‐YP) (Clinton‐McHarg, Carey, Sanson‐Fisher, D'Este, & Shakeshaft, ) and the Childhood Cancer Survivors Study Needs Assessment Questionnaire (CCSS‐NAQ) (Cox et al., ).…”

Section: Resultsmentioning

confidence: 99%

A rapid review of needs assessment tools for post-treatment cancer survivors

et al. 2017

View full text Add to dashboard Cite

Relevant, comprehensive and psychometrically rigorous needs assessment tools are needed to ensure appropriate care is delivered to cancer survivors who have completed treatment. The aim of this rapid review was to identify and describe needs assessment tools that are used in cancer survivors post-treatment, assess their psychometric properties and describe their use in clinical care. The electronic databases Medline, Cochrane Library, CINAHL and PsycINFO were searched. Six studies were identified that described five needs assessment tools used in cancer survivors post-treatment. None of these tools covered all domains of unmet need nor demonstrated adequate evidence of all recommended criteria of validity and reliability. Few had been evaluated for use in a clinical environment. Out of the five tools, the Survivor Unmet Needs Survey (SUNS) showed the strongest psychometric properties. There is little empirical evidence available to guide recommendations on the most appropriate process of conducting needs assessment with cancer survivors once they have completed treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

A rapid review of needs assessment tools for post-treatment cancer survivors

et al. 2017

View full text Add to dashboard Cite

show abstract

“…These tools are available from the NCCN Guidelines for Distress Management . Similarly, the Survivor Unmet Needs Survey (SUNS) and the Short‐Form SUNS (SF‐SUNS) can be used to distinguish between problems which survivors experience and problems which they desire help in managing across a range of life areas, including financial concerns, information and access, and continuity of care …”

Section: Assessment and Management Of Physical And Psychosocial Long‐mentioning

confidence: 99%

“…62 Similarly, the Survivor Unmet Needs Survey (SUNS) and the Short-Form SUNS (SF-SUNS) can be used to distinguish between problems which survivors experience and problems which they desire help in managing across a range of life areas, including financial concerns, information and access, and continuity of care. 64,65 Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest, whereas anxiety is an intense, excessive, and persistent worry and fear about everyday situations. [66][67][68] Both depression and anxiety can initially be screened using a variety of instruments.…”

Section: Distress/depression/anxietymentioning

confidence: 99%

American Cancer Society Colorectal Cancer Survivorship Care Guidelines

El-Shami

Oeffinger

Erb

et al. 2015

CA A Cancer J Clinicians

356

316

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common malignant disease in the United States (U.S.). Almost two-thirds of CRC survivors are living 5 years following diagnosis. The prevalence of CRC survivors is likely to increase dramatically over the coming decades with further advances in early detection and treatment and the aging and growth of the U.S. population. Survivors are at risk for a CRC recurrence, a new primary CRC, other cancers, as well as both short and long-term adverse effects of the CRC and the modalities used to treat it. CRC survivors may also have psychological, reproductive, genetic, social, and employment concerns following treatment. Communication and coordination of care between the treating oncologist and the primary care clinician is critical to effectively and efficiently manage the long-term care of CRC survivors. The following guidelines are intended to assist primary care clinicians in delivering risk-based health care for CRC survivors who have completed active therapy.

show abstract

“…Some of these inhibitors have already been used as antitumor agents, 5,6 showing significant activity against a variety of both hematological and solid tumors at relatively well-tolerated pharmacological doses. [7][8][9] Although little is known about the specific role of HDACs during hematopoiesis, altered HDAC activity has been directly linked with genesis of acute promyelocytic leukemia (APL) [10][11][12] and other types of leukemias. 13 HDACi are able to reduce peripheral blast count in patients with acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS).…”

Section: Introductionmentioning

confidence: 99%

ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias

et al. 2015

View full text Add to dashboard Cite

Altered expression and activity of histone deacetylases (HDACs) have been correlated with tumorigenesis. Inhibitors of HDACs (HDACi) induce acetylation of histone and non-histone proteins affecting gene expression, cell cycle progression, cell migration, terminal differentiation and cell death. Here, we analyzed the regulation of ARHGEF3, a RhoA-specific guanine nucleotide exchange factor, by the HDACi MS275 (entinostat). MS275 is a well-known benzamide-based HDACi, which induces differentiation of the monoblastic-like human histiocytic lymphoma cell line U937 to monocytes/macrophages. Incubation of U937 cells with MS275 resulted in an up regulation of ARHGEF3, followed by a significant enhancement of the marker of macrophage differentiation CD68. ARHGEF3 protein is primarily nuclear, but MS275 treatment rapidly induced its translocation into the cytoplasm. ARHGEF3 cytoplasmic localization is associated with activation of the RhoA/Rho-associated Kinase (ROCK) pathway. In addition to cytoskeletal rearrangements orchestrated by RhoA, we showed that ARHGEF3/RhoA-dependent signals involve activation of SAPK/JNK and then Elk1 transcription factor. Importantly, MS275-induced CD68 expression was blocked by exposure of U937 cells to exoenzyme C3 transferase and Y27632, inhibitors of Rho and ROCK respectively. Moreover, ARHGEF3 silencing prevented RhoA activation leading to a reduction in SAPK/JNK phosphorylation, Elk1 activation and CD68 expression, suggesting a crucial role for ARHGEF3 in myeloid differentiation. Taken together, our results demonstrate that ARHGEF3 modulates acute myeloid leukemia differentiation through activation of RhoA and pathways directly controlled by small GTPase family proteins. The finding that GEF protein modulation by HDAC inhibition impacts on cell differentiation may be important for understanding the antitumor mechanism(s) by which HDACi treatment stimulates differentiation in cancer.

show abstract

Development and validation of the Short-Form Survivor Unmet Needs Survey (SF-SUNS)

Abstract: This study describes the development and psychometric evaluation of the short-form SUNS (SF-SUNS). Future studies should confirm the test-retest reliability and predictive validity of the SF-SUNS utilising large, independent, population-based samples of cancer survivors.

Cited by 46 publications

References 26 publications

A rapid review of needs assessment tools for post-treatment cancer survivors

A rapid review of needs assessment tools for post-treatment cancer survivors

American Cancer Society Colorectal Cancer Survivorship Care Guidelines

ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias

Contact Info

Product

Resources

About